论文部分内容阅读
目的探讨吉西他滨(GEM)化疗结合槐耳综合治疗进展期无法切除胰腺癌的临床疗效。方法对85例无法切除胰腺癌患者进行前瞻性随机对比研究,其中,42例GEM化疗患者归为A组,43例GEM化疗+槐耳治疗患者归为B组。并取同期未行以上治疗的23例患者作为空白对照,归为C组。分析比较各组临床疗效。结果处理后,A、B组血液系统反应发生率差异有统计学意义(P<0.05),而B组IgA、IgG、IgM值,NK细胞、CD3+T细胞亚群百分比及CD4+/CD8+比值均显著高于A组(P<0.05)。A、B组的临床受益率于第3个月时差异有统计学意义(P<0.05),但A、B组间的差异无统计学意义(P>0.05);第6个月时B组显著高于A组(P<0.05)。A、B组的客观有效率差异无统计学意义(P>0.05)。3组的1年累积生存率分别为23.35%、25.76%和10.14%,A、B组显著高于C组(P<0.05),但前2组间的差异无统计学意义(P>0.05)。结论GEM化疗联合槐耳治疗,在改善无法切除胰腺癌客观缓解率及生存时间方面无统计学证据,但对化疗血液系统反应、免疫功能及生存质量等方面有显著疗效。
Objective To investigate the clinical efficacy of gemcitabine (GEM) combined with Huaier comprehensive treatment of advanced pancreatic cancer. Methods A prospective randomized controlled study was performed in 85 patients with unresectable pancreatic cancer. Among them, 42 patients with GEM chemotherapy were classified as group A and 43 patients with GEM chemotherapy + Huaier were assigned to group B. Twenty-three patients who did not receive the above treatment during the same period were enrolled as C group. Analysis and comparison of the clinical efficacy of each group. Results After treatment, there was a significant difference in the incidence of hematological reactions between groups A and B (P <0.05), while IgA, IgG, IgM, NK, CD3 + T cell subsets and CD4 + / CD8 + Significantly higher than the A group (P <0.05). The clinical benefit rate of group A and B had statistical significance at the third month (P <0.05), but there was no significant difference between group A and group B (P> 0.05). Group B Significantly higher than the A group (P <0.05). There was no significant difference in objective efficiency between group A and group B (P> 0.05). The 1-year cumulative survival rates of the 3 groups were 23.35%, 25.76% and 10.14%, respectively. The A and B groups were significantly higher than those of the C group (P <0.05), but there was no significant difference between the two groups (P> 0.05) . Conclusion GEM chemotherapy combined with Huayi Er therapy has no significant effect in improving the objective remission rate and survival time of patients with unresectable pancreatic cancer, but has significant effect on the response to chemotherapy, immune function and quality of life.